Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Abiomed

- PMLiVE

Johnson & Johnson to acquire ADC specialist Ambrx Biopharma for approximately $2bn

The deal includes an ADC candidate in clinical development to treat advanced prostate cancer

- PMLiVE

UK Biobank reveals new data from world’s largest genetic project

The data will accelerate the development of potentially lifesaving treatments and cures

- PMLiVE

Janssen’s Tecvayli approved by EC for reduced dosing frequency in multiple myeloma

Tecvayli was the first BCMA-targeting bispecific antibody to be approved in Europe

- PMLiVE

Janssen’s Talvey granted FDA accelerated approval for difficult-to-treat blood cancer

The therapy showed an overall response rate of more than 70% in a broad range of patients

- PMLiVE

Johnson & Johnson’s attempt to resolve talcum powder lawsuits fails a second time

The company’s subsidiary LTL Management is set to appeal the court’s decision

- PMLiVE

Janssen receives positive CHMP opinion for Talvey in multiple myeloma

More than 50,900 people in Europe were diagnosed with multiple myeloma in 2020

- PMLiVE

Johnson & Johnson sues US government over Medicare drug price negotiation programme

The IRA allows Medicare to negotiate lower prices for a selected group of medicines

- PMLiVE

Janssen signs $2.5bn deal with Nanobiotix for late-stage radiotherapy enhancer

The agreement marks a significant boost to the Johnson & Johnson unit’s oncology pipeline

- PMLiVE

Janssen announces positive phase 2b results for JNJ-2113 in plaque psoriasis

The immune-mediated disease is estimated to affect more than 125 million people worldwide

- PMLiVE

Janssen shares positive phase 3 results for cilta-cel in multiple myeloma

An estimated 35,000 new cases of multiple myeloma will be diagnosed in the US this year

- PMLiVE

Janssen shares positive phase 3 results for erdafitinib in bladder cancer

Urothelial carcinoma accounts for approximately 90% of bladder cancer cases

- PMLiVE

BMS and Janssen’s antithrombotic granted FDA fast track designation

The three indications include ischaemic stroke, acute coronary syndrome and atrial fibrillation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links